SEC Filing Summary: Xenomics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Xenomics, Inc. on June 12, 2006. The report discloses the termination of a material definitive agreement regarding investor and public relations services. Note: The request metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as Xenomics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a corporate governance event and contains no financial statements or performance data.
Material Changes
On May 12, 2006, Xenomics, Inc. provided written notice to Trilogy Capital Partners, Inc. terminating their Letter of Engagement dated January 10, 2005. The termination became effective on June 12, 2006. The agreement covered investor and public relations services.
Outlook and Management Commentary
Management stated that the Company plans to engage another firm for investor and public relations services. The Company is currently reviewing the qualifications of other candidates to replace the terminated provider. No specific risks, contingencies, or unusual items were disclosed beyond the termination event.
Investor Verification Checklist
- Verify the identity of the new investor relations firm selected by Xenomics, Inc.
- Confirm the final settlement terms and any outstanding fees owed to Trilogy Capital Partners, Inc.
- Review subsequent filings to ensure no other material agreements were terminated concurrently.